AnaptysBio (ANAB) PT Lowered to $146 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures gain on tech rebound, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil falls 1% as traders digest escalation in US-Iran strikes
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
AnaptysBio Announces Third Quarter 2018 Financial Results and Provides Pipeline Updates
November 8, 2018 4:15 PM ESTReported positive top-line data from an interim analysis of its ongoing Phase 2a proof-of-concept clinical trial of etokimab in severe eosinophilic asthmaInitiated Phase 2 ECLIPSE trial of etokimab in chronic rhinosinusitis with nasal polyps and Phase 2 POPLAR trial of ANB019 in palmo-plantar pustulosisFour top-line clinical efficacy readouts from wholly-owned pipeline anticipated in 2019
SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the third quarter ended... More
